Plasma concentrations of active simvastatin acid are increased by gemfibrozil

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects

Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02323.x · Cited by 45

The influence of statin characteristics on their safety and tolerability

Angelis, G. D. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00355.x · Cited by 46

Comparison of 3‐Hydroxy‐3‐methylglutaryl Coenzyme A (HMG‐CoA) Reductase Inhibitors (Statins) as Inhibitors of Cytochrome P450 2C8

Tornio, A., Pasanen, M. K., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_134.x · Cited by 44

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?

Backes, J. M., Howard, P. A., Ruisinger, J. F., & Moriarty, P. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m410 · Cited by 43

Statin-Conferred Enhanced Cellular Resistance against Bacterial Pore-Forming Toxins in Airway Epithelial Cells

Statt, S. N., Ruan, J., Hung, L., Chang, C.-Y., Huang, C.-T., Lim, J. H., Li, J., Wu, R., & Kao, C. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0391oc · Cited by 42

Current understanding of hepatic and intestinal OATP-mediated drug–drug interactions

Koenen, A., Kroemer, H. K., Grube, M., & zu Schwabedissen, H. E. M. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.58 · Cited by 42

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

Niemi, M., Backman, J. T., Juntti‐Patinen, L., Neuvonen, M., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02385.x · Cited by 41

Influence of lipid lowering fibrates on P-glycoprotein activity in vitro

Adling-Ehrhardt, M., Lindenmaier, H., Burhenne, J., Haefeli, W. E., & Weiß, J. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.008 · Cited by 41

Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)

Farnier, M., Salko, T., Isaacsohn, J. L., Troendle, A. J., Dejager, S., & Gonasun, L. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00885-3 · Cited by 41

Drug interactions with statins

Čaušević-Ramoševac, A., & Semiz, S. (2013) · Acta Pharmaceutica · doi:10.2478/acph-2013-0022 · Cited by 41

Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?

Keen, H. I., Krishnarajah, J., Bates, T. R., & Watts, G. F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.937422 · Cited by 40

The role of fenofibrate in clinical practice

Zambon, A., & Cusi, K. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.053 · Cited by 40

In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin

Geboers, S., Stappaerts, J., Tack, J. F., Annaert, P., & Augustijns, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.048 · Cited by 40

Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity

Pan, G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_6 · Cited by 40

Statins and PPARα agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment

Johnson, T. E., Zhang, X. D., Shi, S., & Umbenhauer, D. R. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.03.004 · Cited by 38

Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group

Yu, H., Balani, S. K., Chen, W., Cui, D., He, L., Humphreys, W. G., Mao, J., Lai, W. G., Lee, A. J., Lim, H., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059345 · Cited by 37

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

Itkonen, M. K., Tornio, A., Neuvonen, M., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070375 · Cited by 37

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

Kajosaari, L. I., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02158.x · Cited by 37

Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs

Cermak, R., Wein, S., Wolffram, S., & Langguth, P. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.09.018 · Cited by 37

An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)

Lomonaco, R., Chen, J., & Cusi, K. J. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419157 · Cited by 37

Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil

Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K. M., & Lin, J. H. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6037-2 · Cited by 35

Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice

Kivist, K. T., Zukunft, J., Hofmann, U., Niemi, M., Rekersbrink, S., Schneider, S., Luippold, G., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0948-z · Cited by 35

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan

Saito, M., Hirata‐Koizumi, M., Urano, T., Miyake, S., & Hasegawa, R. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00605.x · Cited by 33

Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

Filppula, A. M., Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.92 · Cited by 33

Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of Simvastatin

Vree, T. B., Dammers, E., Ulč, I., Horkovics-Kovats, S., Ryska, M., & Merkx, I. (2003) · The Scientific World JOURNAL · doi:10.1100/tsw.2003.121 · Cited by 32

Successful strategy to improve the specificity of electronic statin–drug interaction alerts

Seidling, H. M., Storch, C. H., Bertsche, T., Senger, C., Kaltschmidt, J., Walter‐Sack, I., & Haefeli, W. E. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0704-x · Cited by 31

Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins

Kunze, A., Poller, B., Huwyler, J., & Camenisch, G. (2015) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2015-0003 · Cited by 32

How Well Tolerated Are Lipid-Lowering Drugs?

Tomlinson, B., Chan, P., & Lan, W. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00003 · Cited by 31

Statins and their interactions with other lipid-modifying medications: safety issues in the elderly

Ho, C. K. M., & Walker, S. W. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611428486 · Cited by 29

Simvastatin interactions with other drugs

Florentin, M., & Elisaf, M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.670633 · Cited by 28

HMG CoA reductase‐inhibitor‐related myopathy and the influence of drug interactions

Huynh, T., Cordato, D. J., Yang, F., Choy, T.-K., Johnstone, K., Bagnall, F., Hitchens, N., & Dunn, R. F. (2002) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2002.00264.x · Cited by 28

Systematic evaluation of 640 FDA drugs for their effect on CD4+Foxp3+ regulatory T cells using a novel cell-based high throughput screening assay

Mao, R., Xiao, W. L., Liu, H., Chen, B., Yi, B., Kraj, P. J., & She, J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.013 · Cited by 27

Combination therapy in the management of mixed dyslipidaemia

Cannon, C. P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01933.x · Cited by 26

Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative

Farnier, M. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303030-00003 · Cited by 27

Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature

McKelvie, P. A., & Dennett, X. (2002) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200206000-00002 · Cited by 27

The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3α‐Hydroxy Isomeric Metabolite

Gustavson, L. E., Schweitzer, S. M., Koehne‐Voss, S., Achari, R., Chira, T. O., Esslinger, H., & Yannicelli, H. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278085 · Cited by 27

Combination therapy in the management of complex dyslipidemias

Davidson, M. H., & Toth, P. P. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137221.16160.b9 · Cited by 27

Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions

Wu, H. C., Mach, J., Gemikonakli, G., Tran, T., Allore, H. G., Gnjidic, D., Howlett, S. E., de Cabo, R., Couteur, D. G. L., & Hilmer, S. N. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab088 · Cited by 26

Design of Single and Multicomponent Drug Spherical Particles with Improved Powder Properties in Water Instead of Organic Solvents: A Case Study of Gemfibrozil

Wang, S., Liu, Y., Guo, S., Yan, H., Li, K., Li, T., Li, T., Chen, M., Gao, Z., & Gong, J. (2022) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.2c03982 · Cited by 26

Optimal lipid modification: the rationale for combination therapy

Backes, J. M., Gibson, C., & Howard, P. A. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.2005.1.4.317 · Cited by 26

Pharmacogenomics and adverse drug reactions: the case of statins

Giorgi, M. A., Caroli, C., Arazi, H. C., & Girolamo, G. D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563734 · Cited by 26

ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans

Zhu, T., Awni, W. M., Hosmane, B. S., Kelly, M. T., Sleep, D. J., Stolzenbach, J. C., Wan, K., Chira, T. O., & Pradhan, R. S. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008325671 · Cited by 26

Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model

Masko, E. M., Alfaqih, M. A., Solomon, K. R., Barry, W. T., Newgard, C. B., Muehlbauer, M. J., Valilis, N. A., Phillips, T. E., Poulton, S. H. M., Freedland, A. R., et al. (2016) · The Prostate · doi:10.1002/pros.23282 · Cited by 27

Evaluating computational models of cholesterol metabolism

Paalvast, Y., Kuivenhoven, J. A., & Groen, A. K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.05.008 · Cited by 25

Identification and Mechanistic Investigation of Drug–Drug Interactions Associated With Myopathy: A Translational Approach

Han, X., Quinney, S. K., Wang, Z., Zhang, P., Duke, J. D., Desta, Z., Elmendorf, J. S., Flockhart, D. A., & Li, L. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.150 · Cited by 25

Prediction of the Metabolic Interaction of Nateglinide with Other Drugs Based on in Vitro Studies

Takanohashi, T., Koizumi, T., Mihara, R., & Okudaira, K. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.409 · Cited by 25

Use ofin vitrotransporter assays to understand hepatic and renal disposition of new drug candidates

Sahi, J. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.409 · Cited by 25

Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization

Ronzier, E., Parks, X. X., Qudsi, H., & Lopes, C. M. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-53700-6 · Cited by 25

Fluvastatin

Corsini, A., Jacobson, T. A., & Ballantyne, C. M. (2004) · Drugs · doi:10.2165/00003495-200464120-00004 · Cited by 26

Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin

Itkonen, M. K., Tornio, A., Neuvonen, M., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065938 · Cited by 24

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model

Lin, W., Ji, T., Einolf, H. J., Ayalasomayajula, S. P., Lin, T., Hanna, I. H., Heimbach, T., Breen, C., Jarugula, V. R., & He, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.01.007 · Cited by 23

Frequency and Clinical Relevance of Drug Interactions with Lovastatin and Simvastatin

Prami, T., Ryynänen, A., Vahlberg, T. J., Irjala, K., Klaukka, T., Huupponen, R., & Laine, K. (2008) · Drug Safety · doi:10.2165/00002018-200831030-00004 · Cited by 24

Drug-Drug Interactions in Prostate Cancer Treatment

Hebenstreit, D., Pichler, R., & Heidegger, I. M. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.016 · Cited by 23

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

Hu, M., Mak, V. W. L., Chu, T., Waye, M. M. Y., & Tomlinson, B. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209787582349 · Cited by 22

Low-dose statin treatment increases prostate cancer aggressiveness

Caro‐Maldonado, A., Camacho, L., Zabala‐Letona, A., Torrano, V., Fernández‐Ruiz, S., Zamacola, K., Arreal, L., Valcárcel-Jiménez, L., Martín-Martín, N., Flores, J. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22217 · Cited by 23

Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform

Venturi, E., Lindsay, C., Lotteau, S. J., Yang, Z., Steer, E., Witschas, K., Wilson, A. D., Wickens, J. R., Russell, A. J., Steele, D. S., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14136 · Cited by 21

Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction

Prieto Garcia, L., Lundahl, A., Ahlström, C., Vildhede, A., Lennernäs, H., & Sjögren, E. (2022) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12837 · Cited by 21

Generation of Bayesian prediction models for OATP-mediated drug–drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3

van de Steeg, E., Venhorst, J., Jansen, H. T., Nooijen, I., DeGroot, J., Wortelboer, H. M., & Vlaming, M. L. H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.004 · Cited by 20

Cerivastatin‐Induced Rhabdomyolysis: 11 Case Reports

Ravnan, S. L., Locke, C., Yee, W. P., & Haase, K. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.533.33674 · Cited by 20

Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions

Dunn, S. P., Holmes, D. R., & Moliterno, D. J. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.10.005 · Cited by 19

Treatment of the Metabolic Disturbances Caused by Antipsychotic Drugs

Baptista, T., Kin, N. M. K. N. Y., & Beaulieu, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443010-00001 · Cited by 19

Adherence to Drug Label Recommendations for Avoiding Drug Interactions Causing Statin-Induced Myopathy–A Nationwide Register Study

Settergren, J., Eiermann, B., & Mannheimer, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069545 · Cited by 18

Gemfibrozil in Combination with Statins—Is It Really Contraindicated?

Wiggins, B. S., Saseen, J. J., & Morris, P. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0571-8 · Cited by 17

Pediatric Statin Administration: Navigating a Frontier with Limited Data

Wagner, J. B., & Abdel‐Rahman, S. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.5.380 · Cited by 17

Consideraciones específicas en la prescripción e intercambio terapéutico de estatinas

García-Sabina, A., Gulín-Dávila, J., Sempere-Serrano, P., González-Juanatey, C., & Martínez-Pacheco, R. (2012) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.02.010 · Cited by 17

Drugs and Rhabdomyolysis: From Liver to Kidney

Barbano, B., Sardo, L., Gasperini, M. L., Gigante, A., Liberatori, M., Lazzaro, G. D., Mario, F. D., Dorelli, B., Amoroso, A., & Cianci, R. (2015) · Current Vascular Pharmacology · doi:10.2174/1570161113666150130151839 · Cited by 16

Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”

Piorkowski, J. D. (2004) · JAMA · doi:10.1001/jama.292.21.2655 · Cited by 16

Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

Knežević, S., Filippi-Arriaga, F., Belančić, A., Božina, T., Mršić‐Pelčić, J., & Vitezić, D. (2024) · Diabetology · doi:10.3390/diabetology5040031 · Cited by 17

Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate

Watanabe, K., Oda, S., Matsubara, A., Akai, S., & Yokoi, T. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.03.001 · Cited by 15

Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships

Iwaki, Y., Lee, W., & Sugiyama, Y. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1681399 · Cited by 14

Co-Medication of Statins with Contraindicated Drugs

Yang, B. R., Seong, J.-M., Choi, N., Shin, J., Lee, J., Kim, Y.-J., Kim, M. S., Park, S., Song, H. J., & Park, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125180 · Cited by 14

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

Nebot, N., Won, C. S., Moreno, V., Muñoz‐Couselo, E., Lee, D., Gasal, E., & Bouillaud, E. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.937 · Cited by 13

Fluvastatin and fluvastatin extended release: a clinical and safety profile

Åsberg, A., & Holdaas, H. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.5.641 · Cited by 13

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

Axelsen, L. N., Poggesi, I., Rasschaert, F., Ruixo, J. J. P., & Bruderer, S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14365 · Cited by 12

Simvastatin profoundly impairs energy metabolism in primary human muscle cells

Mäkinen, S., Datta, N., Nguyen, Y. H., Kyrylenko, P., Laakso, M., & Koistinen, H. A. (2020) · Endocrine Connections · doi:10.1530/ec-20-0444 · Cited by 12

[Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review].

Franco, D., Henao, Y., Monsalve, M., Gutiérrez, F., Hincapié-García, J. A., & Amariles, P. (2013) · PubMed · doi:10.7399/fh.2013.37.6.1077 · Cited by 12

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

Rodon, J. A., Jacobs, C., Chu, Q. S.-C., Rowinsky, E. K., Lopez‐Anaya, A., Takimoto, C. H. M., & Wakelee, H. A. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1770-1 · Cited by 12

Enhanced long-acting simvastatin delivery via effervescent powder-carrying hollow microneedles and nanocrystal-loaded microneedles

Qin, N., Li, M., Vora, L. K., Peng, K., Sabri, A. H. B., Tao, Y., Paredes, A. J., McCarthy, H. O., & Donnelly, R. F. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124691 · Cited by 11

Endothelial barrier protective properties of low molecular weight heparin: A novel potential tool in the prevention of cancer metastasis?

Kevane, B., Egan, K., Allen, S., Maguire, P. B., Neary, E., Lennon, Á., & Áinle, F. N. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12011 · Cited by 11

Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes

Cleves, A. E., & Jain, A. N. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9815-2 · Cited by 10

Increase in Tiagabine Serum Concentration with Coadministration of Gemfibrozil

Burstein, A. H., Boudreau, E. A., & Theodore, W. H. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l080 · Cited by 11

Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity

Stoll, F., Burhenne, J., Lausecker, B., Weiß, J., Thomsen, T., Haefeli, W. E., & Mikus, G. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.161 · Cited by 11

Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation

Davidson, M. H. (2005) · Preventive Cardiology · doi:10.1111/j.0197-3118.2005.04078.x · Cited by 11

Interactions médicamenteuses et hypolipémiants

Becquemont, L. (2003) · Therapies · doi:10.2515/therapie:2003012 · Cited by 11

Local simvastatin and inflammation during periodontal mini‐flap wound healing: Exploratory results

Christiansen, D. L., Killeen, A. C., Ramer‐Tait, A. E., Hattervig, R. L., Nawshad, A., Beede, K., Samson, K. K., & Reinhardt, R. A. (2022) · Journal of Periodontology · doi:10.1002/jper.22-0297 · Cited by 11

Towards Safer and More Predictable Drug Treatment – Reflections from Studies of the First BCPT Prize Awardee

Neuvonen, P. J. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00858.x · Cited by 10

Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet®)

Yamazaki, H., Fujino, H., Kanazawa, M., Tamaki, T., Sato, F., Suzuki, M., & Kitahara, M. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.123.349 · Cited by 10

Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats

Liu, A., Yang, J., Zhao, X., Jiao, X., Zhao, W., Ma, Q., Tang, Z., & Dai, R. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70410-8 · Cited by 9

Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach

Liu, S., Wang, Z., Tian, X., & Cai, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.591854 · Cited by 9

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin

Park, J., Kim, J.-M., Lee, H.-Y., Noh, J., Kim, K., & Park, J.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071491 · Cited by 9

Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation

Corsini, A., & Holdaas, H. (2005) · Renal Failure · doi:10.1081/jdi-200056623 · Cited by 9

Interacciones farmacológicas de las estatinas

Gutiérrez, J. M. Á., Hidalgo, J. D. L.-T., Blesa, P. G., Ruiz, E. M. G., & de Mora, F. N. (2003) · Atención Primaria · doi:10.1016/s0212-6567(03)79163-x · Cited by 9

Persistent Use of Against‐Label Statin‐Fibrate Combinations from 2003–2009 Despite United States Food and Drug Administration Dose Restrictions

Alford, J. C., Saseen, J. J., Allen, R. R., & Nair, K. V. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01090.x · Cited by 9

Physiogenomic Analysis of Statin-Treated Patients: Domain-Specific Counter Effects within the ACACB Gene on Low-Density Lipoprotein Cholesterol?

Ruaño, G., Thompson, P. D., Kane, J. P., Pullinger, C. R., Windemuth, A., Seip, R. L., Kocherla, M., Holford, T. R., & Wu, A. H. B. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.58 · Cited by 9

Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations

Hamilton‐Craig, I. R., Kostner, K., Woodhouse, S. P., & Colquhoun, D. (2012) · International Journal of Evidence-Based Healthcare · doi:10.1111/j.1744-1609.2012.00275.x · Cited by 8

Syndrome de compression des loges bilatéral des membres inférieurs et myonécrose sévère due à l’usage inapproprié de la simvastatine

Chochola, M., Lubanda, J.-C., Skalicka, L., Vařejka, P., Hořejš, J., Prskavec, T., Balík, M., Semrád, M., & Linhart, A. (2008) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2008.07.092 · Cited by 8

Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8

Tod, M. M., Bourguignon, L., Bleyzac, N., & Goutelle, S. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00853-2 · Cited by 8

Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia: a Randomized Control Trial

Kinouchi, K., Ichihara, A., Bokuda, K., Morimoto, S., & Itoh, H. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14860 · Cited by 8

Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems

Molden, E. (2004) · Heart Drug · doi:10.1159/000076934 · Cited by 8

Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases

Sabeel, S., Motaung, B., Ozturk, M., Mukasa, S. L., Kengne, A. P., Blom, D. J., Sliwa, K. S., Nepolo, E., Günther, G., Wilkinson, R. J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039034 · Cited by 7

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Backman, J. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 337

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Schneck, D. W. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 293

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 282